The WASHC2A missense variant has been observed in various cancers as neutral; while the MFSD4B variant has been previously described in gastric and colorectal cancer [31][31][31][31][32], and is likely to cause loss of function of the protein, which is predicted to enable glucose transmembrane transporter activity. Here, SLC60A2 is linked to cancer.